General counsel in the US have come under fire in the past week as the authorities continue to exert regulatory pressure on companies.
Last week pharmaceutical giant Bristol-Myers Squibb announced it had parted company with its general counsel, Richard Willard, following an investigation into the negotiation of a settlement agreement. This related to litigation concerning the use of a drug manufactured by Bristol-Myers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
